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Abstract
Programmable fusogenic vesicles (PFV) are liposomes composed of non-bilayer lipid components stabilized by the
inclusion of an exchangeable poly(ethylene glycol) (PEG)-lipid conjugate. Vesicle destabilization by loss of the PEG-lipid
results in recovery of the inherent fusogenic character. As a result, PFV can be designed to display a long circulation lifetime
after i.v. administration, high accumulation at disease sites and full bioavailability of an encapsulated compound. In the
present study, we investigated the potential application of PFV as carriers for intracellular delivery of antisense
oligodeoxynucleotides (ODN). Antisense phosphorothioate ODN were encapsulated into PFV containing dioleoylphos-
phatidylethanolamine, cholesterol, dioleyldimethylammonium chloride and PEG-ceramides with different carbon chain
length (C8, C14 and C20). In vitro fluorescent microscopy and flow cytometry analysis demonstrated that PFV containing
PEG-ceramide C14 provided enhanced intracellular delivery of FITC-labelled antisense ODN compared to PFV displaying
faster or slower rates of destabilization (containing PEG-ceramide C8 or C20, respectively). Therapeutic efficacy of PFV-
encapsulated antisense ODN against two proto-oncogenes, c-myc and bcl-2, was examined in various cell lines. At antisense
concentrations of 0.5 WM, no significant downregulation of c-myc mRNA levels was observed in HEK293, B16 and MCA207
cells. However, treatment of 518A2 melanoma cells with PFV-encapsulated antisense targeting bcl-2 at concentrations of
0.5 WM and 1.0 WM resulted in reduced bcl-2 mRNA level by about 20% and 25% after 48 h incubation. Free antisense ODN
did not affect bcl-2 mRNA expression at the concentrations used in this study and encapsulated control antisense (reverse
polarity) led to a non-specific increase in mRNA levels. Our results suggest that PFV carriers displaying appropriate rates of
destabilization have the potential to act as intracellular delivery vehicles and may improve the bioavailability and potency of
antisense oligonucleotides. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Antisense oligonucleotides are single-stranded,
synthetic DNA sequences designed to be complemen-
tary to a speci¢c gene. Hybridization with target pre-
mRNA or mRNA through Watson^Crick base-pair-
ing can activate RNase H-mediated degradation of
the RNA strand in RNA^DNA heteroduplexes and
subsequently inhibit gene expression at both mRNA
and protein levels [1^4]. Since the earliest attempts by
Zamecnik and Stephenson [5,6], antisense as a poten-
tial therapeutic agent against neoplastic and infec-
tious diseases has been tested in numerous research
laboratories around the world. Although one anti-
sense drug received marketing approval in 1998 and
several antisense compounds are in clinical trials [7],
much of the preclinical work in this area has not
been translated into therapeutic applications. One
of the major obstacles to broad application of anti-
sense technology is related to intracellular delivery.
Fundamentally, these large polar molecules are un-
suited to passive di¡usion across cell membranes in
their ‘naked’ form [8]. Even if they make their en-
trance into cells through £uid-phase pinocytosis or
receptor-mediated endocytosis, internalized antisense
oligodeoxynucleotides (ODN) remain mostly within
vacuoles [9]. To compensate for this poor intracellu-
lar delivery, high doses are usually needed to achieve
desirable therapeutic activities; however, these may
trigger an acute toxicity response associated with
high plasma ODN concentrations. In addition, exter-
nal antisense can interact with cell surface proteins
and interfere with normal cellular function in a non-
sequence speci¢c manner [10].
These problems with intracellular availability of
free antisense have prompted studies into the devel-
opment of carrier systems to enhance cellular uptake
of antisense. Liposomes have been widely used in
pharmaceutical applications as a delivery system for
drugs and other bioactive molecules. These lipid
vesicles are biodegradable, non-immunogenic, and
able to encapsulate a wide variety of therapeutic
agents. For antisense delivery, cationic liposomes
have been widely used. These liposomes contain a
cationic lipid, for DNA binding, and a non-bilayer-
forming lipid to promote fusion with the plasma
membrane. While cationic liposome^ODN complex
system can work well in vitro [11,12], they are inher-
ently unstable and apt to fuse to each other or the
nearest available cell. This severely limits their suit-
ability for systemic application. Recent development
in liposomal formulation technology has identi¢ed a
new type of liposome, termed programmable fuso-
genic vesicles (PFV) [13]. These liposomes contain
cholesterol, charged lipid dioleyldimethylammonium
chloride, and non-bilayer-forming lipid dioleoylphos-
phatidylethanolamine, stabilized by exchangeable
poly(ethylene glycol) (PEG)-lipid conjugates [14].
They are initially stable in the circulation and pro-
tected from rapid clearance by the reticuloendothelial
system (RES) as a result of the hydrophilic polymer
coating. They can be designed to exhibit a long cir-
culation time, allowing for accumulation at disease
sites [15]. Upon loss of the PEG-lipid conjugates,
which can be varied from minutes to hours, these
vesicles become unstable and fusogenic [14]. In pre-
vious studies, PFV have shown promising anticancer
drug delivery potential [16].
In the current study, we evaluated PFV as a deliv-
ery system for antisense molecules. The delivery of
encapsulated antisense was characterized in di¡erent
PFV formulations and compared to free antisense.
The biological e¡ects of antisense constructs de-
signed against the proto-oncogenes, c-myc and bcl-
2, were examined. The results reported in this study
demonstrate that PFV systems with optimized rates
of destabilization are promising delivery vehicles for
antisense ODN.
2. Materials and methods
2.1. Materials
1,2-sn-Dioleoylphosphatidylethanolamine (DOPE)
was purchased from Avanti Polar Lipids (Alabaster,
AL). N,N-Dioleyl-N,N-dimethyl ammonium chloride
(DODAC) and monomethoxypolyethylene2000glycol
succinate-(C8:0, C14:0 or C20:0 ceramide) (PEG-C8,
C14 or C20) were kindly provided by Inex Pharma-
ceuticals (Vancouver, Canada). [3H]Cholesteryl hex-
adecyl ether ([3H]CHE) was bought from NEN Life
Science (Boston, MA). Cholesterol, HEPES, sodium
thiocyanate (NaSCN), and DEAE-Sepharose CL-6B
were purchased from Sigma (Oakville, ON). Dialysis
tubing (SpectraPor 12,000 to 14,000 mwco) was ob-
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tained from Fisher Scienti¢c (Ottawa, ON). Media
and fetal calf serum for cell cultures, Trizol reagent,
M-MLV reverse transcriptase, random hexamers and
Taq DNA polymerase were originally obtained from
Gibco BRL-Life Technologies (Burlington, ON).
Propidium iodine was bought from Molecular
Probes (Eugene, OR). Antisense c-myc (AS), £uores-
cein isothiocyanate (FITC)-epidermal growth factor
receptor (EGFR) and mismatched control ODN
(SAS) were the generous gifts from Inex Pharmaceut-
icals. Antisense bcl-2 (G3139, AS) and reverse-polar-
ity control ODN (G3622, RP) were originally syn-
thesized by Genta (Lexington, MA).
2.2. Cell lines and cell culture
Four di¡erent cell lines were investigated in gene
regulation studies: HEK293, B16, MCA207 and
518A2. The human embryonic kidney cell line
HEK293 and murine melanoma cell line B16 were
obtained from ATCC and maintained in Dulbecco’s
modi¢ed Eagle’s medium (HEK293) or minimum es-
sential medium (B16). Chemically induced murine
¢brosarcoma MCA207 cells were obtained from
Dr. P. Joshi (Inex Pharmaceuticals, Vancouver, Can-
ada) and maintained in RPMI 1640 medium. Human
melanoma 518A2 cells were obtained from the Brit-
ish Columbia Cancer Agency and cultured in
DMEM. All cells were grown in their designated
medium supplemented with 10% fetal calf serum at
37‡C in 5% CO2. In addition, 2 mM L-glutamine was
supplemented to B16 and MCA207 cells and 1 mM
sodium pyruvate to B16 cells. For typical antisense
delivery and gene regulation experiments, cells were
seeded on 25 cm2 Nunclon tissue culture £asks
(Nunc, Roskilde, Denmark). In all experiments, cells
were seeded 18^20 h prior to the treatment.
2.3. Antisense and control ODN
Both antisense and control sequences were fully
phosphorothioated single strand ODN. Antisense
c-myc (5P-AAC GTT GAG GGG CAT-3P) was com-
plementary to the ¢rst ¢ve translation start codons of
the human c-myc mRNA and the control ODN (5P-T
AAG CAT ACG GGG TGT-3P) was a 16-mer mis-
matched sequence that preserved the G-quartet mo-
tif. Antisense bcl-2 (5P-TCT CCC AGC GTG CGC
CAT-3P) was complementary to the ¢rst six transla-
tion start codons of the human bcl-2 mRNA and the
control ODN for this antisense (5P-TAC CGC GTG
CGA CCC TCT-3P) had the same sequence as that of
the antisense but in a reverse-polarity arrangement.
A 15-mer, ¢ve-prime FITC-labelled antisense to the
gene stop codon of EGFR, FITC-EGFR, (5P-CCG
TGG TCA TGC TCC-3P) was used to characterize
the e⁄cacy of in vitro delivery of ODN into cells.
2.4. PFV preparation and encapsulation of
antisense ODN
Both antisense and control ODN were encapsu-
lated within PFV based on an electrostatic interac-
tion between the cationic lipid DODAC and the neg-
ative charges on the ODN phosphate groups. Brie£y,
DOPE, cholesterol, DODAC and PEG-ceramide
(C8, C14 or C20) were dissolved in 100% ethanol at
molar ratios of 35:45:15:5. Trace amounts of
[3H]CHE (approx. 0.01 WCi/mg lipid) were included
in the mixture as a lipid marker. The lipid mixture
(50 mM) was added to an aqueous solution of anti-
sense (1 mg/ml) in 200 mM NaCl bu¡ered with
20 mM HEPES, pH 7.4 (HBS) such that the ¢nal
antisense:lipid ratio was 0.07:1 (w/w) and the ¢nal
ethanol concentration was 30%. The vesicles were
subsequently extruded through 100 nm pore size
polycarbonate ¢lters to create unilamellar vesicles
using an Extruder (Lipex Biomembranes, Vancouver,
BC) [17]. Ethanol was removed by dialysing the
vesicles against HBS overnight at room temper-
ature. Free and externally bounded antisense were
removed by dialysis against 150 mM NaCl, 50 mM
NaSCN, 20 mM HEPES, pH 7.4 for 5 h followed by
ion exchange chromatography (DEAE-Sepharose
CL-6B). The ¢nal antisense:lipid ratio in loaded
PFV was approx. 0.03^0.04:1 (w/w) and the encap-
sulation e⁄ciency of the PFV was in the range of 43^
57%. The mean diameter of antisense loaded PFV
ranged from 100 to 120 nm as determined by qua-
si-elastic light scattering using a Nicomp Model 270
particle sizer. Vesicles for cell culture studies were
sterilized by terminal ¢ltration through a 0.2 Wm
HT Tu¡ryn membrane ¢lter (Gelman Science, Ann
Arbor, MI).
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2.5. Preparation of cationic liposome^ODN
complexes
Cationic liposomes were prepared using a standard
procedure. Brie£y, DOPE and DODAC were dis-
solved in benzene:methanol (95:5, v/v) at the molar
ratio of 50:50. The lipid mixture was lyophilized and
subsequently hydrated in distilled H2O. Vesicles were
prepared by extrusion through 100 nm pore size
polycarbonate ¢lters after freeze and thawing cycles
[18].
Preformed cationic liposomes were mixed with
ODN in sterile water and incubated at room temper-
ature for 30 min before adding to the cells. The con-
centrations of total lipid and ODN in the complex
preparation were adjusted according to the desired
charge ratio. In this study, the ¢nal charge ratio of
cationic lipids:ODN was 1.3:1 (+:3) for bcl-2 anti-
sense and 1.5:1 for c-myc.
2.6. In vitro antisense delivery studies and
£ow cytometry analysis
All intracellular delivery studies were carried out
with HEK293 cells. In a typical experiment, free
FITC-EGFR, empty PFV, or FITC-EGFR-loaded
PFV were added to the cells (5U105 cells/£ask),
yielding a ¢nal antisense concentration of 0.2 WM.
At various time points (0, 1, 2 or 4 h), cells were
trypsinized, pelleted, washed and resuspended in
phosphate-bu¡ered saline (PBS). Cell-associated
FITC £uorescent intensity was analysed using a
FACSort dual-laser £ow cytometer (Becton Dickin-
son, San Jose, CA). Propidium iodide (PI) was added
to the cell suspension (1 Wg/ml) prior to the reading
as an indicator for cell membrane permeability.
FITC and PI were detected in channel one (FL1,
Vem = 530 þ 15 nm) and channel two (FL2, Vem =
585 þ 21 nm), respectively. A minimum of 10 000
events was collected for each sample. The data
were analysed using CellQuest software (Becton-
Dickinson). Antisense delivery and cellular compart-
mentalization were further assessed by £uorescent
microscopy using a Zeiss Axiovert S100 inverted
microscope equipped with an epi£uorescence attach-
ment. Photographs were taken using Kodak Ekta-
chrome P1600 ¢lm.
2.7. Downregulation of c-myc and bcl-2 mRNA using
free antisense, antisense^liposome complexes or
PFV-encapsulated antisense
Cells were cultured in 25 cm2 £asks at an initial
density of 5U105 cells/£ask. Antisense was delivered
either as free ODN, by cationic liposome complexes,
or by PFV. The control cells were treated with the
same volume of HBS (PFV delivery) or distilled H2O
(liposome complex delivery). Using antisense^lipo-
some complexes, cells were treated in a serum-free
culture environment. Cells were incubated in se-
rum-free media either up to the time point (9 8 h)
or for 4 h after which the media were replaced with
serum-containing media for longer time points (24 h).
In the case of antisense delivery using PFV, cells
were maintained in serum-containing media. At var-
ious time points (4, 8, 24 or 48 h), media were re-
moved and cells were directly lysed in the £ask. Total
RNA was extracted using Trizol reagent following
the manufacturer’s instructions.
Quantitation of c-myc and bcl-2 mRNA levels was
carried out using reverse transcription-polymerase
chain reaction (RT-PCR) following a standard pro-
Table 1
Primers used for PCR ampli¢cation and expected length of DNA fragment
Gene Primer pair Product size (bp)
bcl-2 (human) 5P-ATGGCGCACGCTGGGAGAAC-3P 327
5P-GCGGTAGCGGCGGGAGAAGT-3P
c-myc (human) 5P-TAATTCCAGCGAGAGGCAGAGG-3P 618
5P-ACGTAGGAGGGCGAGCAGAG-3P
c-myc (mouse) 5P-CGCTGGGAAACTTTGCCCAT-3P 492
5P-CGCCGTCATCGTCTTCCCTT-3P
L-actin 5P-TGATCCACATCTGCTGGAAGGTGG-3P 524 (human)
5P-GGACCTGACTGACTACCTCATGAA-3P 523 (mouse)
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cedure [19]. Brie£y, ¢rst strand cDNA was synthe-
sized from 2.5 Wg total RNA using M-MLV reverse
transcriptase and random hexamers in 50 mM Tris^
HCl (pH 8.3), 75 mM KCl, 10 mM DTT, and 2 mM
dNTPs. The reaction was allowed to proceed for 1 h
at 37‡C and stopped by incubation of reaction mix-
ture at 95‡C for 5 min. Reverse transcription reac-
tion products subsequently underwent PCR ampli¢-
cation for the detection of speci¢c genes. Aliquots
(3 Wl) of RT reaction products were ampli¢ed sepa-
rately for bcl-2, c-myc and L-actin (internal standard)
by PCR in 20 mM Tris^HCl (pH 8.4), 50 mM KCl,
1.5 mM MgCl2, 0.8 mM dNTPs, 0.25 WM each of the
gene speci¢c primers and 1.5 U of Taq DNA poly-
merase. The primers for each speci¢c gene and the
sizes of ampli¢cation products are listed in Table 1.
DNA ampli¢cation was performed using a Perkin-
Elmer DNA thermocycler under the following con-
ditions: 30 s at 94‡C followed by 1.5 min at 65‡C for
20^35 cycles. Appropriate cycle numbers were deter-
mined experimentally for each of the interested genes
in each cell line. Ampli¢ed products (10 Wl) were
electrophoresed in 1.5% (w/v) agarose gel stained
by ethidium bromide. Levels of relative band inten-
sity, corrected on the basis of L-actin level, were
quantitated using a digital camera (Eagle Eye II,
Stratagene) coupling with ImageQuant software
(Molecular Dynamic, CA). The ¢nal values of
c-myc or bcl-2 mRNA abundance were expressed as
percentages of the untreated control cells.
2.8. Statistical analysis
Data from gene regulation studies were evaluated
with one-way ANOVA using SigmaStat software.
Di¡erences among treatment groups were further
evaluated with the Student^Newman^Keuls test. A
statistically signi¢cant di¡erence was reported if
P6 0.05.
3. Results
3.1. Delivery of FITC-labelled antisense to HEK293
cells: free and PFV-encapsulated ODN
The ability of PFV to deliver antisense molecules
e⁄ciently to HEK293 cells was examined using £ow
cytometry. FITC-labelled antisense (EGFR) was in-
troduced to the cell medium as the free oligonucleo-
tide, in the presence of empty PFV, or encapsulated
in PFV containing PEG-ceramide C14. As shown in
Fig. 1, cells treated with free antisense demonstrated
little or no uptake. The mean £uorescence in these
cells was not signi¢cantly di¡erent from that in con-
trol cells. In contrast, at the same antisense concen-
tration (0.2 WM), cells incubated with PFV-encapsu-
lated antisense exhibited e⁄cient accumulation of
FITC-EGFR, to levels 20 times higher than obtained
for free antisense. As can be seen, cellular uptake of
free antisense was also enhanced in the presence of
empty PFV, but not to the same level seen for en-
capsulated ODN. Destabilization of PFV through
exchange of PEG-lipid conjugates will expose the
cationic surface. Binding of free antisense may then
occur with subsequent introduction of this antisense
into cells either through fusion of the complex with
the plasma membrane [20^22] or by complex endo-
cytosis [23,24]. Nevertheless, the most e¡ective deliv-
ery of antisense was achieved for PFV-encapsulated
ODN.
3.2. In£uence of PEG-ceramide acyl chain length on
PFV-mediated delivery of antisense
The rate of PFV destabilization is governed by the
exchange rate of the PEG-ceramide component. In
turn, this rate is determined by the ceramide N-acyl
chain length which ‘anchors’ the conjugate within the
Fig. 1. Time course of FITC-labelled antisense uptake, dis-
played as mean £uorescence, by HEK293 cells upon exposure
to free antisense (P), free antisense plus empty PFV (F) and
PFV encapsulated antisense (7). Untreated cells were presented
as the control (b).
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lipid bilayer. As the N-acyl chain is shortened, the
rate of lipid exchange and vesicle destabilization in-
creases [25]. To evaluate the in£uence of N-acyl chain
length on delivery of antisense molecules in vitro, we
examined PFV systems containing PEG-ceramide of
varying N-acyl chain length, i.e., C8, C14, or C20,
respectively. As shown in Fig. 2, for all three PFV
formulations the intensity of mean £uorescence in
cells was elevated compared to free antisense. Signi¢-
cant di¡erences were seen, however, in the time
course and magnitude of ODN delivery for the dif-
ferent PFV formulations. When antisense was deliv-
ered by PFV containing PEG-ceramide C14, cell-as-
sociated £uorescence intensity increased steadily over
4 h. In contrast, when antisense was delivered by
PFV containing PEG-ceramide C8 or C20, cell-asso-
ciated £uorescence intensity exhibited an initial
jump, similar to that seen for the PEG-ceramide
C14 formulation, followed by a decline over 4 h.
After 4 h, the highest mean £uorescence was ob-
served in cells treated with PFV containing PEG-cer-
amide C14, which was about twice as high as samples
incubated with PFV containing PEG-ceramide C8 or
C20.
3.3. Antisense intracellular compartmentalization
following delivery by PFV with PEG-ceramides of
varying N-acyl chain length
Flow cytometry provides information on FITC-
ODN association with cells but does not allow deter-
mination of intracellular distribution. We therefore
examined cells after incubation with free or PFV-en-
capsulated ODN by £uorescence microscopy. As for
the £ow cytometry studies, HEK293 cells were incu-
bated with antisense encapsulated in PFV containing
PEG-ceramides of varying N-acyl chain length. After
4 h incubation, cells were washed with PBS and ob-
served under phase contrast and £uorescence micros-
copy. Signi¢cant di¡erences in the cellular distribu-
tion of FITC-labelled antisense, as a function of PFV
composition, were apparent (Fig. 3). In the case of
PFV containing PEG-ceramide C8 (Fig. 3A,B), £uo-
rescence microscopy revealed a punctate distribution
of FITC-ODN predominantly distributed around the
cell surface. No signi¢cant intracellular £uorescence
was seen. In contrast, FITC-EGFR delivered using
PFV containing PEG-ceramide C14 (Fig. 3C,D) was
predominantly internalized, exhibiting di¡use £uo-
rescence, mainly in the cytoplasm. In the case of
PFV containing PEG-ceramide C20 (Fig. 3E,F), £uo-
rescence was mainly observed on the cell surface.
This pattern was similar to that observed for PFV
containing PEG-ceramide C8 ; however, the FITC-
EGFR distribution was somewhat less punctate.
These observations are consistent with the rate of
vesicle destabilization governing the e⁄ciency of
antisense internalization. In light of the £uorescence
microscopy results it appears likely that the initial
increase in cell-associated £uorescence seen by £ow
cytometry (Fig. 2) represents surface-absorbed PFV
and not internalized antisense, particularly in the
case of formulation containing PEG-ceramides with
C8 and C20 N-acyl chain lengths.
3.4. Antisense e¡ects on c-myc mRNA expression
Based on the £uorescence microscopy studies, it is
clear that antisense molecules can be e¡ectively de-
livered into cells using PFV formulations incorporat-
ing PEG-ceramide C14. The next question addressed
concerned the subsequent biological e¡ects of anti-
sense ODN on target genes. This was ¢rst investi-
gated using a 15-mer antisense construct targeting
the proto-oncogene c-myc. This antisense construct
has been shown previously to inhibit c-myc protein
expression and cell proliferation of human leukaemic
cell line HL-60 [26]. Antitumour e¡ects are also dem-
Fig. 2. In£uence of PEG-ceramide acyl chain length on cellular
uptake of FITC-labelled antisense by HEK293 cells. Antisense
was delivered as free antisense (P), by PFV containing PEG-
ceramide C8 (b), PEG-ceramide C14 (S), or PEG-ceramide C20
(F). Untreated cells were presented as control (a).
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onstrated in several animal models [27^29]. We ex-
amined the antisense e¡ects on three cell lines: in
addition to HEK293 cells, two mouse tumour cell
lines were investigated for comparison. As described
in Section 2, free antisense, empty PFV, PFV-encap-
sulated control ODN (SAS), or PFV-encapsulated
antisense ODN (AS) were introduced to cells at a
¢nal ODN concentration of 0.5 WM (or equivalent
PFV concentration). Levels of c-myc mRNA were
analysed after 4, 8, 24, or 48 h incubation. Empty
PFV were used to monitor possible changes in gene
expression in cells responding to cationic lipids.
Levels of mRNA, standardized against L-actin, are
shown in Fig. 4. Despite the e⁄cient cellular delivery
previously demonstrated, no clear antisense e¡ects at
the mRNA level were seen for any of the cell lines
studied over 48 h. It appeared that after 24 h treat-
ment with encapsulated antisense ODN, both
HEK293 and B16 cells showed a slight reduction in
mRNA abundance compared to free antisense and
control ODN treatments (Fig. 4A,B). However, this
reduction was not statistically signi¢cant. We also
observed non-speci¢c stimulation of mRNA levels
when cells were exposed to both ODN and lipo-
somes. This was seen in all of the cell lines treated
with control ODN after 24 h incubation. The mech-
anism for this upregulation e¡ect is not clear. How-
ever, this might partially mask or o¡set an antisense-
Fig. 3. Intracellular localization of FITC-labelled antisense in HEK293 cells after 4 h incubation. Antisense was delivered by PFV
containing PEG-ceramide C8 (A,B), PEG-ceramide C14 (C,D), or PEG-ceramide C20 (E,F).
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mediated reduction. It is also possible that the encap-
sulated antisense was not completely bioavailable to
the target genes. To test this possibility, we carried
out another set of experiments using cationic lipo-
some^ODN complexes for delivery [20,30]. Free anti-
sense, cationic liposome, control ODN^liposome
complexes, or antisense^liposome complexes were
added to HEK293 cells or B16 cells at the same
ODN concentration as that of PFV delivery. Down-
regulation of c-myc mRNA was evaluated after 2, 4,
or 8 h treatment. As shown in Fig. 5, downregulation
was seen with B16 cells after 4 and 8 h incubation,
but this represented a maximum decrease of only
about 20% relative to free antisense and control cells.
Downregulation of c-myc mRNA was also exhibited
with HEK293 cells after 2 h treatment. However, this
might not be a true antisense e¡ect because a similar
decrease in mRNA level was displayed by cells
treated with cationic liposomes alone. It has been
suggested that the target gene reduction may be at-
tributed to the toxicity of cationic liposome com-
plexes instead of a true antisense e¡ect [31]. Results
from our cell toxicity studies, however, indicated a
reciprocal relationship between cell viability and
c-myc expression. Upon exposing cells to cationic
liposomes or liposome^ODN complexes for 4 or
8 h, both HEK293 and B16 cells exhibited varied
levels of cytotoxic e¡ect. Severe cytotoxicity (50^
60% reduction of cell viability) was displayed in cells
that were treated with liposome^ODN complexes
(data not shown). Corresponding to the reduction
of viability, all cells, except the B16 cells treated
with antisense^liposome complexes, exhibited ele-
vated c-myc mRNA expression compared to the con-
trol cells (Fig. 5). Our data showed that with similar
levels of cytotoxic e¡ect among di¡erent treatments,
or higher in the case of control ODN^liposome com-
Fig. 5. Expression of c-myc mRNA in HEK293 cells (A) and
B16 cells (B) upon exposure to free antisense (a), cationic lipo-
some (S), control ODN^liposome complexes (SAS-C) (P), or
antisense ODN^liposome complexes (AS-C) (F). Control cells
(b) were treated with an equal volume of distilled water. Values
are presented as means þ S.E.M. (n = 2).
Fig. 4. Expression of c-myc mRNA in HEK293 cells (A), B16
cells (B) and MCA207 cells (C) upon exposure to HBS (control,
open bar), free antisense (shaded), empty PFV (diagonal
hatched), PFV-encapsulated control ODN (SAS) (horizontal
hatched), or PFV-encapsulated antisense (AS) (cross-hatched).
The abundance of c-myc mRNA was quanti¢ed by RT-PCR as
described in Section 2. Values are presented as means þ S.E.M.
(n = 2).
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plexes, only cells treated with antisense^liposome
complexes displayed target gene reduction. This
seems to suggest that the downregulation e¡ect of
c-myc antisense observed under our experimental
conditions is not a direct cause of cytotoxicity. The
most striking observation from the cationic liposome
complex delivery studies is the reciprocal relationship
between cell viability and c-myc expression. It is pos-
sible that the c-myc is overexpressed to compensate
the cell death induced by liposomal complexes. The
mechanism for this upregulation of c-myc mRNA
has not been fully understood. In summary, no con-
sistent or signi¢cant reduction in c-myc mRNA level
was seen for antisense delivered using either cationic
liposome complexes or PFV.
3.5. Antisense e¡ects on bcl-2 mRNA expression
The inability to demonstrate downregulation of
c-myc mRNA levels might re£ect the binding a⁄nity
of the ODN construct for its complementary se-
quence, or rapid turnover of c-myc mRNA. To fur-
ther investigate the e⁄cacy of the PFV delivery sys-
tem, we therefore studied an 18-mer antisense
construct against the proto-oncogene bcl-2. In pre-
vious studies, this antisense has been proved a potent
therapeutic agent. When delivered by cationic lipo-
some complexes, this antisense has successfully inhib-
ited gene expression at both mRNA and protein lev-
els and prevented cell growth by inducing apoptosis
in human melanoma cell lines (including 518A2) [32].
Our preliminary experiments on 518A2 cells con-
¢rmed that bcl-2 mRNA expression was signi¢cantly
reduced after exposure to antisense^liposome com-
plexes for 24 h. This reduction also appeared to be
ODN concentration dependent (data not shown).
Further examination indicated that the downregula-
tion e¡ect was antisense speci¢c. As shown in Fig. 6,
exposing 518A2 cells to antisense^cationic liposome
complexes at a ¢nal ODN concentration of 0.5 WM,
bcl-2 mRNA levels were reduced by 60% after 24 h
incubation. The reverse polarity control ODN (RP)
produced less than 30% reduction in message levels.
Using this antisense construct and the 518A2 cell
line, we examined the PFV delivery system. Cells
were exposed to free antisense, empty PFV, PFV-
encapsulated control RP, or PFV-encapsulated AS
for 24 or 48 h at two antisense concentrations:
0.5 WM and 1.0 WM. The level of mRNA expression
under di¡erent treatments is illustrated in Fig. 7 and
the numerical results are shown in Fig. 8. An anti-
sense speci¢c downregulation e¡ect was clearly ob-
served after 48 h treatment by antisense encapsulated
in PFV at both concentrations. With PFV delivery,
mRNA expression in cells was reduced, relative to
the control cells, by about 20% at an antisense con-
centration of 0.5 WM (Fig. 8A). In the case of cells
treated with PFV containing the control, reverse po-
Fig. 7. Representative RT-PCR analysis of bcl-2 mRNA expres-
sion in 518A2 cells after 48 h exposure to HBS (lane 1), free
antisense (lanes 2 and 6), empty PFV (lanes 3 and 7), PFV-en-
capsulated control ODN (lanes 4 and 8), or PFV-encapsulated
antisense ODN (lanes 5 and 9). The ¢nal antisense concentra-
tion is 0.5 WM (lanes 2^5) or 1.0 WM (lanes 6^9), respectively.
Fig. 6. Expression of bcl-2 mRNA in 518A2 cells upon expo-
sure to free antisense, cationic liposome, control ODN^lipo-
some complexes (RP-C), or antisense^liposome complexes (AS-
C) for 24 h at a ¢nal antisense ODN concentration of 0.5 WM.
Control cells were treated with an equal volume of distilled
water. The abundance of bcl-2 mRNA was quanti¢ed by RT-
PCR. Values are presented as means þ S.E.M. (n = 4). *Signi¢-
cant di¡erence between AS-C and the rest of the treatment
groups (P6 0.05).
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larity, ODN, an upregulation of bcl-2 mRNA was
seen. Compared to this control ODN, therefore,
the reduction of mRNA expression in cells treated
with PFV-encapsulated antisense was about 30%.
When the antisense concentration was increased to
1.0 WM, the mRNA level was further reduced, by
about 25% compared to the control cells (Fig. 8B).
However, cells treated with PFV containing the con-
trol ODN showed an even higher stimulation on
mRNA expression. The di¡erence in mRNA levels
between antisense versus control ODN was therefore
about 40%. It was also apparent from Fig. 8 that a
lag period existed between initial treatment of cells
with bcl-2 antisense in PFV, and message downregu-
lation. This lag period was not seen when antisense
was delivered using cationic liposome complexes.
This delay also appeared to be independent of
antisense concentration. Further in contrast to the
results obtained with cationic liposome complexes,
delivery of control, reverse polarity ODN in PFV
did not result in a non-sequence speci¢c reduction
in mRNA.
4. Discussion
For many applications, an ‘ideal’ drug delivery
carrier should possess the following properties: it
should be stable and remain in the circulation system
long enough to allow maximum accumulation at the
disease site; once reaching the site, it should become
fusogenic or ‘leaky’ making encapsulated drugs bio-
available to the target cells. Conventional liposomal
carriers that exhibit long circulation lifetime and high
disease site deposition are designed to be physically
stable and resistant to leakage or fusion. As a result
encapsulated drugs may not be adequately released
from the carriers even after they have accumulated at
the target sites. For a stable liposome to become
leaky requires an intrinsic change to its biophysical
or structural properties. In programmable fusogenic
vesicles, this is achieved by using non-lamellar-form-
ing lipids, DOPE, which in isolation adapt the hex-
agonal HII phase, cholesterol and DODAC. This
mixture is stabilized in a bilayer organization only
by the presence of an exchangeable component,
PEG-lipid [14]. The PEG-lipid component can also
inhibit protein binding, and subsequent vesicle clear-
ance, after intravenous administration of PFV [33^
35]. As a consequence of their hydrophilic polymer
chain, however, PEG-lipids, such as PEG-ceramide,
can desorb from the PFV membrane and exchange
to other hydrophobic binding sites [36]. Gradually,
with loss of PEG-ceramide, the initially stable PFV
will be destabilized resulting in either fusion to an
adjacent membrane and/or release of encapsulated
compounds [13,14,37]. An important factor in de-
signing an e⁄cient carrier system is to control the
rate of vesicle destabilization. If the vesicles destabi-
lize in the circulation, accumulation at the disease
site will be compromised. The rate of PFV destabili-
zation is controlled by the PEG-lipid component. By
varying the hydrophobic ‘anchor’ domain, one can
modulate the fusion process over minutes to hours
[25]. For the delivery of large polar molecules such as
antisense ODN, PFV also need to interact directly
with cell membranes. Simply releasing antisense in
the vicinity of target cells, following PFV destabili-
Fig. 8. Expression of bcl-2 mRNA in 518A2 cells upon expo-
sure to HBS (control, open bar), free antisense (shaded), empty
PFV (diagonal hatched), PFV-encapsulated control ODN (RP)
(horizontal hatched), or PFV-encapsulated antisense ODN (AS)
(cross-hatched) at a ¢nal antisense concentration of 0.5 WM (A)
or 1.0 WM (B). Values are presented as means þ S.E.M. (n = 3^
5). *Signi¢cant di¡erence between AS-loaded PFV and RP-
loaded PFV (P6 0.05).
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zation, does not address the problem of uptake into
the cell cytoplasm. The inclusion of a cationic lipid,
DODAC, is therefore intended to promote the inter-
action between vesicles and cell membranes [38].
Subsequent fusion of the carrier with the plasma
membrane, or an endosomal membrane following
endocytosis, would provide an opportunity for the
encapsulated oligonucleotide to be released directly
into the cytoplasm.
The results reported in the current study demon-
strate that antisense delivery and cell internalization
can be achieved when the oligonucleotide is encapsu-
lated in an optimized PFV. In vitro, cellular uptake
of antisense is signi¢cantly enhanced when the PFV
carrier undergoes destabilization over several hours
i.e. for PFV containing PEG-ceramide C14 [13].
More importantly, with this delivery system, anti-
sense can be largely delivered into the cell cytoplasm.
When PFV destabilization occurs over much shorter
or longer time periods, i.e. for systems containing
PEG-ceramides C8 and C20, respectively, e⁄cient in-
tracellular delivery of antisense is not observed. In
the case of PFV containing PEG-ceramide C8, it is
likely that rapid loss of the stabilizing component
results in aggregation of the carriers before they
can interact with the cell surface. In contrast, systems
containing PEG-ceramide C20 would not be expected
to destabilize over the time course of the experiment
[25,36] and hence vesicle fusion or antisense release is
not anticipated. It is important to note that an opti-
mal PFV formulation for in vitro applications may
not be the ideal candidate for in vivo use. Carrier
accumulation at, for example, tumour sites is depen-
dent on circulation lifetime in the blood [15] and
hence a slower rate of destabilization may be re-
quired to maximize tumour loading.
After delivery into cells, antisense ODN can exert
their biological activity through one of the following
mechanisms: interrupting RNA interaction with ri-
bosomes; blocking mRNA passage from nucleus to
cytoplasm; hybridizing with the cytoplasmic target
mRNA and resulting in the arrest of translation;
and triggering cleavage of the hybridized mRNA
by RNase H [39,40]. To achieve e⁄cient downregu-
lation of mRNA levels, it is suggested that RNase H
enzymatic cleavage should be involved [41^43].
RNase H, a ubiquitous group of endonucleases
that cleave the RNA strand in RNA^DNA hetero-
duplexes, is mainly located in the nucleus [44]. The
level of RNase H and its activity vary between cell
lines and are also dependent on antisense concentra-
tion [45]. The e⁄cacy of RNase H cleavage of RNA^
DNA hybrids depends on sequence binding a⁄nity,
which is antisense molecule speci¢c [46]. Obviously,
to get a maximum antisense e¡ect, all three compo-
nents, i.e. enzyme, antisense ODN and target
mRNA, should be located in the same subcellular
compartment. Currently, we do not completely
understand the mechanism(s) by which antisense
reaches the nucleus after being delivered into cells
by liposomes. Previous studies have shown e¡ective
nuclear localization of antisense and downregulation
of mRNA expression following delivery as cationic
liposome complexes [32,47,48]. In our present study,
therefore, cationic liposome^ODN complexes were
used as a positive control in message downregulation
studies. In the case of c-myc antisense, all tested cell
lines were unresponsive to the antisense ODN at the
concentration used. Even with cationic liposome
complex delivery, message downregulation is mini-
mal. We suggest that the poor biological e¡ect
detected for this antisense may be due to a poor
RNase H enzyme activity, which is dependent upon
both cellular and ODN factors. For antisense bcl-2,
on the other hand, promising speci¢c antisense
e¡ects are observed with both delivery systems. Com-
pared to cationic liposome complex delivery, PFV
systems require a longer period before mRNA
downregulation is observed. This lag period may
relate to the time required for PFV destabilization.
When higher concentrations of bcl-2 antisense in
PFV were administered to cells (1.0 WM compared
to 0.5 WM) only a small additional decrease in
mRNA level was observed. This may re£ect satura-
tion of binding sites of PEG-ceramide in vitro and
hence decreased e⁄ciency of vesicle destabilization.
Additional experiments are undergoing to address
this issue.
An important di¡erence between the use of cation-
ic liposome complexes and PFV is that serum inter-
feres with antisense delivery using cationic complexes
[49]. Accordingly, incubations must be performed in
serum-free media. As illustrated in the present work,
this is not a limitation for PFV and is clearly an
important consideration for subsequent in vivo ap-
plications.
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